Apnimed, Inc.
Research Apnimed, Inc. (APMD) on Bullrun: market cap USD 691.07M, P/E 7.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 691.07M
- P/E7.1
- Financial periodQ2 2026
- RevenueUSD 12.08M
- Net incomeUSD 125.94M
- Free cash flow-USD 18.45M
- Gross margin90.0%
Valuation Snapshot
latest market cap is USD 691.07M; P/E is 7.1.
Peer valuation comparison
Latest P/E is 7.1x versus a Healthcare sector median of 21.69x (67.3% below).
Latest P/E is 7.1x versus a United States median of 23.63x (70.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 38.47M | -USD 932.00K | -USD 77.83M | 82.6% | -0.03 | USD 41.89M | USD 41.52M | -USD 372.78M |
| FY2024 | USD 8.01M | -USD 111.31M | -USD 110.28M | 58.0% | -3.87 | USD 68.35M | USD 1.10M | -USD 248.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-19 | USD 691.07M | 7.1 | n/a | n/a |
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Apnimed, Inc.'s market cap?
Apnimed, Inc.'s market capitalization is USD 691.07M.
What is Apnimed, Inc.'s P/E ratio?
Apnimed, Inc.'s price-to-earnings (P/E) ratio is 7.1.
What does Apnimed, Inc. do?
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.